Análise de custo-efetividade da abiraterona para câncer de próstata metastático resistente à castração em pacientes com uso prévio de quimioterapia
Leal, Lisiane Freitas; Alves, Rafael José Vargas; Polanczyk, Carisi Anne; Ribeiro, Rodrigo Antonini.
J. bras. econ. saúde (Impr.)
; 10(2): 126-133, Agosto/2018.
Artigo em Português | LILACS, ECOS | ID: biblio-914924
Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.
The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients.
Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.